The optimal treatment duration of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis in children
1.Department of Pediatrics, Xiguan Community Health Care Center, Jinhua, 321017; 2.Department of Otorhinolaryngology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325027; 3.Department of Otorhinolaryngology, Wenrong Hospital, Jinhua, 321017; 4.Department of Pediatrics, Oriental Hospital, Jinhua, 322000
QIAN Xubo1,NI Liyan2,XU Chengbo3, et al. The optimal treatment duration of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis in children[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(5): 359-.
Abstract：Objective: To define the optimal treatment duration of mometasone furoate nasal spray (MFNS) in children with chronic rhinosinusitis (CRS). Methods: We did a randomized and controlled study of 267 children with CRS from three hospitals in Jinhua between September, 2013 and August, 2014. Of these patients aged from 3.0 to 16.3 years, 86 patients were randomly assigned to group one, 88 to group two, and 93 to control group. Group one received MFNS for 6 weeks, group two for 8 weeks, and control group for 12 weeks, respectively. All groups received mucolytics for 6 weeks and antimicrobial agents for 10-14 days at the beginning of the treatment. Results: The incidences of posterior nasal drip, cough, anterior nasal drip, nasal blockage, and hawk were 67.00%, 65.90%, 40.80%, 35.20%, and 6.40%, respectively. There were no significant differences in disappearance times of these clinical manifestations among the three groups (P>0.05). At the end of the treatment, Lund-Mackay score in group one was significantly higher than those of group two and control group (P<0.017); but no difference was observed between group two and control group (P>0.017). Conclusion: The optimal duration of MFNS treatment in children with CRS is 8 weeks.
